The mission of the Breast Cancer Program (BC) is to conduct high-impact breast cancer research through collaborations among its members and with members of other Cancer Center programs. With a portfolio of basic, translational, clinical and population-based research, BC focuses on three broad themes: Theme 1 is focused on understanding mechanisms of responsiveness to endocrine therapy. Key accomplishments in this theme include the award of a Center for Cancer Systems Biology that supported development of the first roadmap for mathematically modeling estrogen receptor signaling (Clarke). Theme 2 elucidates nutritional, environmental and genetic risk factors of breast cancer susceptibility. Noteworthy accomplishments include demonstrating the role of epigenetic modifications in establishing and maintaining transgenerational mammary cancer susceptibility in rats (Hilakivi-Clarke). Theme 3 explores clinical, therapeutic, molecular, and social factors that impact the treatment and progression of breast cancer. Key accomplishments include a study led by Swain that changed clinical practice by showing the survival benefit of adding pertuzumab to standard therapy in metastatic HER2 positive breast cancer. Led by Robert Clarke, PhD, DSc, and Claudine Isaacs, MD, the Program has 24 members representing eight Georgetown University departments and two MedStar hospitals. The Program also includes 10 breast cancer patient advocates. From 2009 to 2012, 42 therapeutic trials have accrued 231 patients. BC research is highly collaborative and interdisciplinary, and would not be possible outside of a Cancer Center that adds value through substantial institutional support ($11.6M) and access to nine state-of-the-art Shared Resources, all of which are used by BC members. Members are supported by $5.1M in peer-reviewed funding (direct cost), including $3.1 M of direct NCI funding. BC is home to three multi-investigator grants. Productivity is demonstrated by 357 cancer-related, peer-reviewed publications, of which 35% are intra- and/or interprogrammatic, the latter including collaborators from all three other Programs. 52% of publications involve external collaborations. Additional noteworthy features include: a strong junior investigator mentorship program;development of novel investigator-initiated clinical trials across MWHC and MGUH with correlative studies using cellular reprogramming and functional genomic technologies;and outreach and research initiatives in the Black and Hispanic communities within our catchment area.
Death rates from breast cancer are higher in the Washington, DC region than elsewhere in the U.S. and mortality is greater in Black women than in any other group. Thus, BC fills a great need through its emphasis on understanding mechanisms of responsiveness and risk factors that will address some of the unique cancer-related challenges in our catchment area.
|Lai, Chih-Hsin; Lai, Ying-Jung J; Chou, Feng-Pai et al. (2016) Matriptase Complexes and Prostasin Complexes with HAI-1 and HAI-2 in Human Milk: Significant Proteolysis in Lactation. PLoS One 11:e0152904|
|AlHossiny, Midrar; Luo, Linlin; Frazier, William R et al. (2016) Ly6E/K Signaling to TGFÎ² Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance. Cancer Res 76:3376-86|
|Chung, Arlene E; Jensen, Roxanne E; Basch, Ethan M (2016) Leveraging Emerging Technologies and the ""Internet of Things"" to Improve the Quality of Cancer Care. J Oncol Pract 12:863-866|
|Brown, Lindsay; Gutherz, Samuel; Kulick, Catherine et al. (2016) Profile of retigabine-induced neuronal apoptosis in the developing rat brain. Epilepsia 57:660-70|
|Hunegnaw, Ruth; Vassylyeva, Marina; Dubrovsky, Larisa et al. (2016) Interaction Between HIV-1 Nef and Calnexin: From Modeling to Small Molecule Inhibitors Reversing HIV-Induced Lipid Accumulation. Arterioscler Thromb Vasc Biol 36:1758-71|
|Taylor, Kathryn L; Hoffman, Richard M; Davis, Kimberly M et al. (2016) Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Cancer Epidemiol Biomarkers Prev 25:1240-50|
|Allen, Megan; Ghosh, Suhasini; Ahern, Gerard P et al. (2016) Protease induced plasticity: matrix metalloproteinase-1 promotes neurostructural changes through activation of protease activated receptor 1. Sci Rep 6:35497|
|Boca, Simina M; Nishida, Maki; Harris, Michael et al. (2016) Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLoS One 11:e0153461|
|Spikol, Emma D; Laverriere, Caroline E; Robnett, Maya et al. (2016) Zebrafish Models of Prader-Willi Syndrome: Fast Track to Pharmacotherapeutics. Diseases 4:|
|Cheema, Amrita K; Maier, Irene; Dowdy, Tyrone et al. (2016) Chemopreventive Metabolites Are Correlated with a Change in Intestinal Microbiota Measured in A-T Mice and Decreased Carcinogenesis. PLoS One 11:e0151190|
Showing the most recent 10 out of 883 publications